262 related articles for article (PubMed ID: 30567982)
1. Resistance to Second-Generation HIV-1 Maturation Inhibitors.
Urano E; Timilsina U; Kaplan JA; Ablan S; Ghimire D; Pham P; Kuruppu N; Mandt R; Durell SR; Nitz TJ; Martin DE; Wild CT; Gaur R; Freed EO
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567982
[TBL] [Abstract][Full Text] [Related]
2. Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.
Urano E; Ablan SD; Mandt R; Pauly GT; Sigano DM; Schneider JP; Martin DE; Nitz TJ; Wild CT; Freed EO
Antimicrob Agents Chemother; 2016 Jan; 60(1):190-7. PubMed ID: 26482309
[TBL] [Abstract][Full Text] [Related]
3. A single G10T polymorphism in HIV-1 subtype C Gag-SP1 regulates sensitivity to maturation inhibitors.
Ghimire D; Kc Y; Timilsina U; Goel K; Nitz TJ; Wild CT; Gaur R
Retrovirology; 2021 Apr; 18(1):9. PubMed ID: 33836787
[TBL] [Abstract][Full Text] [Related]
4. Insight into the mechanism of action of EP-39, a bevirimat derivative that inhibits HIV-1 maturation.
Neyret A; Gay B; Cransac A; Briant L; Coric P; Turcaud S; Laugâa P; Bouaziz S; Chazal N
Antiviral Res; 2019 Apr; 164():162-175. PubMed ID: 30825471
[TBL] [Abstract][Full Text] [Related]
5. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).
Adamson CS; Ablan SD; Boeras I; Goila-Gaur R; Soheilian F; Nagashima K; Li F; Salzwedel K; Sakalian M; Wild CT; Freed EO
J Virol; 2006 Nov; 80(22):10957-71. PubMed ID: 16956950
[TBL] [Abstract][Full Text] [Related]
6. Structural and functional insights into the HIV-1 maturation inhibitor binding pocket.
Waki K; Durell SR; Soheilian F; Nagashima K; Butler SL; Freed EO
PLoS Pathog; 2012; 8(11):e1002997. PubMed ID: 23144615
[TBL] [Abstract][Full Text] [Related]
7. Effects of an HIV-1 maturation inhibitor on the structure and dynamics of CA-SP1 junction helices in virus-like particles.
Gupta S; Louis JM; Tycko R
Proc Natl Acad Sci U S A; 2020 May; 117(19):10286-10293. PubMed ID: 32341150
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors.
Lin Z; Cantone J; Lu H; Nowicka-Sans B; Protack T; Yuan T; Yang H; Liu Z; Drexler D; Regueiro-Ren A; Meanwell NA; Cockett M; Krystal M; Lataillade M; Dicker IB
PLoS Pathog; 2016 Nov; 12(11):e1005990. PubMed ID: 27893830
[TBL] [Abstract][Full Text] [Related]
9. Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457).
Adamson CS; Waki K; Ablan SD; Salzwedel K; Freed EO
J Virol; 2009 May; 83(10):4884-94. PubMed ID: 19279107
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat.
Adamson CS; Sakalian M; Salzwedel K; Freed EO
Retrovirology; 2010 Apr; 7():36. PubMed ID: 20406463
[TBL] [Abstract][Full Text] [Related]
11. The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles.
Nguyen AT; Feasley CL; Jackson KW; Nitz TJ; Salzwedel K; Air GM; Sakalian M
Retrovirology; 2011 Dec; 8():101. PubMed ID: 22151792
[TBL] [Abstract][Full Text] [Related]
12. A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat.
Lu W; Salzwedel K; Wang D; Chakravarty S; Freed EO; Wild CT; Li F
Antimicrob Agents Chemother; 2011 Jul; 55(7):3324-9. PubMed ID: 21502630
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice.
Keller PW; Adamson CS; Heymann JB; Freed EO; Steven AC
J Virol; 2011 Feb; 85(4):1420-8. PubMed ID: 21106735
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat.
Margot NA; Gibbs CS; Miller MD
Antimicrob Agents Chemother; 2010 Jun; 54(6):2345-53. PubMed ID: 20308382
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.
Fun A; van Maarseveen NM; Pokorná J; Maas RE; Schipper PJ; Konvalinka J; Nijhuis M
Retrovirology; 2011 Aug; 8():70. PubMed ID: 21864346
[TBL] [Abstract][Full Text] [Related]
16. The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation.
Checkley MA; Luttge BG; Soheilian F; Nagashima K; Freed EO
Virology; 2010 Apr; 400(1):137-44. PubMed ID: 20172577
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 Maturation: Lessons Learned from Inhibitors.
Kleinpeter AB; Freed EO
Viruses; 2020 Aug; 12(9):. PubMed ID: 32858867
[TBL] [Abstract][Full Text] [Related]
18. Structure-Activity Relationships of the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PF-46396.
Murgatroyd C; Pirrie L; Tran F; Smith TK; Westwood NJ; Adamson CS
J Virol; 2016 Sep; 90(18):8181-97. PubMed ID: 27384665
[TBL] [Abstract][Full Text] [Related]
19. Insights into the activity of maturation inhibitor PF-46396 on HIV-1 clade C.
Ghimire D; Timilsina U; Srivastava TP; Gaur R
Sci Rep; 2017 Mar; 7():43711. PubMed ID: 28252110
[TBL] [Abstract][Full Text] [Related]
20. Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage.
Nowicka-Sans B; Protack T; Lin Z; Li Z; Zhang S; Sun Y; Samanta H; Terry B; Liu Z; Chen Y; Sin N; Sit SY; Swidorski JJ; Chen J; Venables BL; Healy M; Meanwell NA; Cockett M; Hanumegowda U; Regueiro-Ren A; Krystal M; Dicker IB
Antimicrob Agents Chemother; 2016 Jul; 60(7):3956-69. PubMed ID: 27090171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
